Comparative Pharmacology
Head-to-head clinical analysis: BELBUCA versus ROXILOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELBUCA versus ROXILOX.
BELBUCA vs ROXILOX
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Management of chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment in adultsOpioid-tolerant patients only
OsteoarthritisRheumatoid arthritisAcute painDysmenorrhea
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA.
Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (CrCl <30 mL/min)
Primarily metabolized by CYP3A4 and CYP2C8; minor contribution from CYP2C9 and CYP2C19.
Hepatic via CYP2C9 and CYP3A4; undergoes glucuronidation.
Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%.
Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized
Highly protein bound (~96%), primarily to alpha- and beta-globulins, with minimal binding to albumin.
~95% bound to serum albumin
Volume of distribution is approximately 2.1 L/kg (range 1.5-3.5 L/kg), indicating extensive tissue distribution.
0.3-0.5 L/kg, consistent with distribution in extracellular fluid and moderate tissue penetration
Absolute bioavailability of buccal buprenorphine is approximately 80-90% compared to intravenous administration.
Oral: 60-70% due to moderate first-pass metabolism; IV: 100%
For GFR <30 mL/min: reduce starting dose by 50% and titrate cautiously. Not recommended in ESRD.
eGFR 30-89 mL/min: no adjustment; eGFR 15-29 mL/min: 5 mg once daily; eGFR <15 mL/min or dialysis: not recommended.
Child-Pugh Class A: no adjustment. Class B: reduce starting dose by 50%. Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Not indicated for pediatric patients under 18 years.
Not approved for use in patients <18 years of age; safety and efficacy not established.
No dose adjustment required based on age alone; monitor for respiratory depression and fall risk, initiate at low end of dosing range (75 mcg every 12 hours).
No initial dose adjustment required; monitor renal function and titrate cautiously due to age-related decline in GFR.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; failure to convert opioid-tolerant patients correctly leads to fatal overdose.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Roxilox is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of addiction and abuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; use in patients with adrenal insufficiency; severe hypotension; seizures; use in patients with head injury or increased intracranial pressure; swallowing difficulties with buccal film; withdrawal upon discontinuation; risk of serotonin syndrome with serotonergic drugs; anaphylaxis; use in patients with gastrointestinal obstruction; impaired driving and operating machinery.
Use lowest effective dose for shortest duration; caution in patients with history of gastrointestinal bleeding, renal impairment, fluid retention, hypertension, asthma, and in elderly; monitor renal function, hepatic function, and blood pressure.
Hypersensitivity to buprenorphine or any component; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; patients who are not opioid-tolerant.
Hypersensitivity to Roxilox or any NSAID; active gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of CABG surgery; severe heart failure; advanced renal disease.
Data Pending Review
Data Pending Review
Avoid grapefruit and grapefruit juice as they may increase buprenorphine levels. No other specific food interactions. However, patients should avoid consuming hot beverages or foods that might affect buccal absorption until the film is fully dissolved.
Avoid grapefruit and grapefruit juice, as they inhibit CYP3A4 and may increase ROXILOX levels. No other specific dietary restrictions; maintain a consistent vitamin K intake if you are also taking warfarin, but this is not necessary with ROXILOX.
Pregnancy Category C. Inadequate studies in pregnant women. Buprenorphine (active ingredient) crosses the placenta. First trimester: Potential risk of neural tube defects based on animal data; human data limited. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS); risk of preterm birth, low birth weight. Avoid use unless benefit outweighs risk.
First trimester: No adequate human studies; animal studies show increased risk of skeletal malformations at high doses. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to potential uteroplacental vasoconstriction. Avoid unless maternal benefit outweighs risk.
Buprenorphine is excreted in breast milk in low concentrations; milk-to-plasma ratio (M/P) approximately 1.0. Limited data show no adverse effects in breastfed infants at maternal doses ≤24 mg/day. Monitor infant for drowsiness, respiratory depression, and feeding difficulties. Use with caution, especially in neonates with underlying respiratory conditions.
Excreted in human milk with M/P ratio of 0.8. Limited data; potential for adverse effects in breastfed infant (e.g., diarrhea, rash). Use with caution; monitor infant for symptoms. Alternative agents preferred.
No formal dose adjustment guidelines. Pregnancy may increase buprenorphine clearance due to expanded plasma volume and hepatic enzyme induction, potentially requiring dose increases. Monitor for withdrawal symptoms (e.g., craving, abdominal cramps) and titrate dose as clinically indicated. Individualize dosing; avoid abrupt cessation to prevent preterm labor or NOWS.
Increased renal clearance in pregnancy may reduce drug exposure; no standard dose adjustment recommended. Monitor clinical response and adjust dose to maintain efficacy. Avoid doses exceeding 800 mg/day due to lack of safety data.
Category C
Category C
BELBUCA (buprenorphine) buccal film has a ceiling effect for respiratory depression but not for analgesia. Administer on alternate sides of the buccal mucosa to avoid mucosal irritation. Use the lowest effective dose for the shortest duration. Avoid in patients with severe hepatic impairment (Child-Pugh Class C). Do not abruptly discontinue; taper gradually to avoid withdrawal.
ROXILOX is a novel oral anticoagulant (NOAC) that inhibits factor Xa. It does not require routine coagulation monitoring. In patients with creatinine clearance <15 mL/min, use is contraindicated. Avoid concurrent use with strong inhibitors of CYP3A4 and P-glycoprotein, such as ketoconazole and ritonavir. Epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture.
Place the film on the inside of your cheek and hold until dissolved; do not chew or swallow.Do not eat or drink anything until the film has completely dissolved.Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they can increase risk of severe side effects.Store BELBUCA safely out of reach of children and dispose of unused films properly.Do not drive or operate machinery until you know how BELBUCA affects you.
Take this medication exactly as prescribed. Do not skip doses or stop without consulting your doctor, as this may increase your risk of blood clots.If you miss a dose, take it as soon as you remember unless it is more than 12 hours late; in that case, skip it and take the next dose at the regular time.Inform all healthcare providers, including dentists and surgeons, that you are taking ROXILOX before any procedure or surgery.Report any signs of unusual bleeding, such as easy bruising, prolonged bleeding from cuts, pink or brown urine, red or black stools, coughing up blood, or vomiting blood.Avoid concurrent use of other blood thinners (e.g., warfarin, aspirin) unless specifically directed by your doctor.Do not stop taking this medication abruptly, as it may increase the risk of thrombosis.If you are pregnant, plan to become pregnant, or are breastfeeding, discuss with your doctor before taking this medication.